Tigecycline Coverage of Staphylococcus haemolyticus
Yes, tigecycline does cover Staphylococcus haemolyticus with excellent in vitro activity, and the FDA drug label specifically lists S. haemolyticus among organisms with demonstrated susceptibility to tigecycline. 1
FDA-Approved Coverage
The FDA drug label for tigecycline explicitly includes Staphylococcus haemolyticus in its spectrum of activity 1. According to the label, at least 90% of S. haemolyticus isolates exhibit an in vitro minimum inhibitory concentration (MIC) at or below the susceptible breakpoint for tigecycline. However, the label notes an important caveat: the efficacy of tigecycline in treating clinical infections caused by S. haemolyticus has not been established in adequate and well-controlled clinical trials 1.
Clinical and Research Evidence
Multiple surveillance and research studies confirm tigecycline's activity against S. haemolyticus:
A German surveillance study found that all staphylococci tested were tigecycline-susceptible, with only one exception being a single S. haemolyticus isolate 2. This demonstrates >99% susceptibility.
In bone marrow transplant patients with CNS bacteremia, tigecycline showed MIC₅₀ and MIC₉₀ values of 0.25 and 0.5 μg/mL respectively against S. haemolyticus isolates 3, indicating excellent activity.
Tigecycline demonstrated anti-biofilm activity against S. haemolyticus, with biofilm inhibitory concentrations (BIC) ranging from 0.062 to 1 μg/mL when combined with rifampicin 4. This is particularly relevant since S. haemolyticus frequently causes biofilm-associated infections on medical devices.
Important Clinical Considerations
Resistance Patterns
While tigecycline generally maintains excellent activity, resistance to tigecycline has been documented in S. haemolyticus isolates from healthcare settings 5. A study from Ghana identified tigecycline resistance in S. haemolyticus from a neonatal ICU, including in isolates from patients never previously exposed to the drug, suggesting potential horizontal resistance transfer.
Dosing Recommendations
For serious infections where tigecycline is considered:
- Standard dosing: 100 mg IV loading dose, then 50 mg IV every 12 hours 6
- High-dose regimen (for severe infections with resistant organisms): 200 mg loading dose, then 100 mg IV every 12 hours 7
Critical Limitations
Tigecycline should NOT be used for S. haemolyticus bacteremia as monotherapy 8. The drug has a large volume of distribution resulting in low serum levels (Cmax does not exceed 0.87 mg/L with standard dosing) 7, making it unsuitable for bloodstream infections.
For intra-abdominal infections involving S. haemolyticus, tigecycline is an appropriate choice 8 due to high peritoneal penetration.
Combination Therapy
When treating S. haemolyticus biofilm-associated infections, tigecycline combined with rifampicin shows superior activity compared to daptomycin-rifampicin combinations 4. The tigecycline/rifampicin combination was particularly effective against ica-independent biofilms formed by S. haemolyticus.
Practical Algorithm for Use
- Confirm susceptibility testing - Always obtain MIC values; do not rely solely on in vitro data
- Identify infection site:
- Intra-abdominal infection → Tigecycline appropriate
- Skin/soft tissue infection → Tigecycline appropriate
- Bacteremia/bloodstream → Avoid tigecycline, use vancomycin, daptomycin, or linezolid instead
- Biofilm-associated device infection → Consider tigecycline + rifampicin combination
- Check for multidrug resistance - If MIC ≤1 mg/L and other agents resistant, tigecycline is a viable option
- Use combination therapy when possible, especially for severe infections 7
Key Pitfalls to Avoid
- Do not use tigecycline for bacteremia - low serum levels make it ineffective 8, 7
- Do not assume susceptibility - resistance is emerging even in non-exposed populations 5
- Avoid monotherapy for serious infections - combination with another active agent is recommended 7
- Be aware of the FDA black box warning - tigecycline has shown increased all-cause mortality versus comparators in pooled clinical trials 9, 10